Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder
Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compar...
Gespeichert in:
| Veröffentlicht in: | International clinical psychopharmacology 1997-10, Vol.12 Suppl 6, p.S27-S27 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S27 |
|---|---|
| container_issue | |
| container_start_page | S27 |
| container_title | International clinical psychopharmacology |
| container_volume | 12 Suppl 6 |
| creator | Tiller, John W.G Bouwer, Colin Behnke, Kirsten |
| description | Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compared with that of the selective serotonin reuptake inhibitor fluoxctine. The target dose of moclobemide was 450 mg/day in the dose range of 300–600 mg/day, while the target dose for fluoxetine was 20 nig/day in the dose range of 10–30 mg/day. There were two consecutive studies. The first was an 8-week short-term study of acute adverse events, tolerabilily and efficacy. The efficacy data showed no significant difference between moclobemide and fluoxetine. Evaluation of the tolerability in a long-term study of up to 1 year is still in progress. A review of the moclobemide safety database for panic disorder with 624 patients showed a marginal increase in events with moclobemide compared with placebo for insomnia (11.2%), dizziness (4.5%) and dry mouth (3.7%), with rates for headaches and nausea lower for moclobemide than placebo.These data suggest moclobemide is a well tolerated and effective treatment for panic disorder. |
| doi_str_mv | 10.1097/00004850-199710006-00006 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00004850_199710006_00006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9466172</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3296-7e313781061c72fc0f553ab7c8e2c0717ad323a8f019e0b6f10edad01032f71a3</originalsourceid><addsrcrecordid>eNp1kctKAzEUhoMotVYfQZiF29Fzkpkk406KN6i40fWQyYWOzqUkHWrf3tTWWQhmE3L-7w_hCyEJwjVCIW4grkzmkGJRCIwHnu5G_IhMMRMszWUujskUKJcpMsxPyVkIHwAUsMgmZFJknKOgU7J46XXTV7atjU1c7xPVfdV2vU1MHXpvrA-3iYqBHkLSd0n7h16prtYje05OnGqCvTjsM_L-cP82f0oXr4_P87tFqhkteCosQyYkAkctqNPg8pypSmhpqQaBQhlGmZIuPtZCxR2CNcoAAqNOoGIzIvf3at-H4K0rV75uld-WCOXOT_nrpxz9_Ix4rF7uq6uhaq0ZiwchMb865Cpo1TivOl2HEaOYUSFZxLI9tumbdZT02Qwb68ulVc16Wf73O-wbkmJ8QQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Tiller, John W.G ; Bouwer, Colin ; Behnke, Kirsten</creator><creatorcontrib>Tiller, John W.G ; Bouwer, Colin ; Behnke, Kirsten</creatorcontrib><description>Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compared with that of the selective serotonin reuptake inhibitor fluoxctine. The target dose of moclobemide was 450 mg/day in the dose range of 300–600 mg/day, while the target dose for fluoxetine was 20 nig/day in the dose range of 10–30 mg/day. There were two consecutive studies. The first was an 8-week short-term study of acute adverse events, tolerabilily and efficacy. The efficacy data showed no significant difference between moclobemide and fluoxetine. Evaluation of the tolerability in a long-term study of up to 1 year is still in progress. A review of the moclobemide safety database for panic disorder with 624 patients showed a marginal increase in events with moclobemide compared with placebo for insomnia (11.2%), dizziness (4.5%) and dry mouth (3.7%), with rates for headaches and nausea lower for moclobemide than placebo.These data suggest moclobemide is a well tolerated and effective treatment for panic disorder.</description><identifier>ISSN: 0268-1315</identifier><identifier>EISSN: 1473-5857</identifier><identifier>DOI: 10.1097/00004850-199710006-00006</identifier><identifier>PMID: 9466172</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott-Raven Publishers</publisher><subject>Adult ; Anxiety - drug therapy ; Anxiety - psychology ; Benzamides - adverse effects ; Benzamides - therapeutic use ; Biological and medical sciences ; Blood Pressure - drug effects ; Female ; Fluoxetine - adverse effects ; Fluoxetine - therapeutic use ; Humans ; Male ; Medical sciences ; Moclobemide ; Monoamine Oxidase Inhibitors - adverse effects ; Monoamine Oxidase Inhibitors - therapeutic use ; Neuropharmacology ; Panic Disorder - drug therapy ; Panic Disorder - psychology ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Serotonin Uptake Inhibitors - adverse effects ; Serotonin Uptake Inhibitors - therapeutic use ; Time Factors</subject><ispartof>International clinical psychopharmacology, 1997-10, Vol.12 Suppl 6, p.S27-S27</ispartof><rights>Lippincott-Raven Publishers.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2142783$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9466172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tiller, John W.G</creatorcontrib><creatorcontrib>Bouwer, Colin</creatorcontrib><creatorcontrib>Behnke, Kirsten</creatorcontrib><title>Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder</title><title>International clinical psychopharmacology</title><addtitle>Int Clin Psychopharmacol</addtitle><description>Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compared with that of the selective serotonin reuptake inhibitor fluoxctine. The target dose of moclobemide was 450 mg/day in the dose range of 300–600 mg/day, while the target dose for fluoxetine was 20 nig/day in the dose range of 10–30 mg/day. There were two consecutive studies. The first was an 8-week short-term study of acute adverse events, tolerabilily and efficacy. The efficacy data showed no significant difference between moclobemide and fluoxetine. Evaluation of the tolerability in a long-term study of up to 1 year is still in progress. A review of the moclobemide safety database for panic disorder with 624 patients showed a marginal increase in events with moclobemide compared with placebo for insomnia (11.2%), dizziness (4.5%) and dry mouth (3.7%), with rates for headaches and nausea lower for moclobemide than placebo.These data suggest moclobemide is a well tolerated and effective treatment for panic disorder.</description><subject>Adult</subject><subject>Anxiety - drug therapy</subject><subject>Anxiety - psychology</subject><subject>Benzamides - adverse effects</subject><subject>Benzamides - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Female</subject><subject>Fluoxetine - adverse effects</subject><subject>Fluoxetine - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Moclobemide</subject><subject>Monoamine Oxidase Inhibitors - adverse effects</subject><subject>Monoamine Oxidase Inhibitors - therapeutic use</subject><subject>Neuropharmacology</subject><subject>Panic Disorder - drug therapy</subject><subject>Panic Disorder - psychology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Time Factors</subject><issn>0268-1315</issn><issn>1473-5857</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctKAzEUhoMotVYfQZiF29Fzkpkk406KN6i40fWQyYWOzqUkHWrf3tTWWQhmE3L-7w_hCyEJwjVCIW4grkzmkGJRCIwHnu5G_IhMMRMszWUujskUKJcpMsxPyVkIHwAUsMgmZFJknKOgU7J46XXTV7atjU1c7xPVfdV2vU1MHXpvrA-3iYqBHkLSd0n7h16prtYje05OnGqCvTjsM_L-cP82f0oXr4_P87tFqhkteCosQyYkAkctqNPg8pypSmhpqQaBQhlGmZIuPtZCxR2CNcoAAqNOoGIzIvf3at-H4K0rV75uld-WCOXOT_nrpxz9_Ix4rF7uq6uhaq0ZiwchMb865Cpo1TivOl2HEaOYUSFZxLI9tumbdZT02Qwb68ulVc16Wf73O-wbkmJ8QQ</recordid><startdate>199710</startdate><enddate>199710</enddate><creator>Tiller, John W.G</creator><creator>Bouwer, Colin</creator><creator>Behnke, Kirsten</creator><general>Lippincott-Raven Publishers</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199710</creationdate><title>Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder</title><author>Tiller, John W.G ; Bouwer, Colin ; Behnke, Kirsten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3296-7e313781061c72fc0f553ab7c8e2c0717ad323a8f019e0b6f10edad01032f71a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Anxiety - drug therapy</topic><topic>Anxiety - psychology</topic><topic>Benzamides - adverse effects</topic><topic>Benzamides - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Female</topic><topic>Fluoxetine - adverse effects</topic><topic>Fluoxetine - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Moclobemide</topic><topic>Monoamine Oxidase Inhibitors - adverse effects</topic><topic>Monoamine Oxidase Inhibitors - therapeutic use</topic><topic>Neuropharmacology</topic><topic>Panic Disorder - drug therapy</topic><topic>Panic Disorder - psychology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tiller, John W.G</creatorcontrib><creatorcontrib>Bouwer, Colin</creatorcontrib><creatorcontrib>Behnke, Kirsten</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>International clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tiller, John W.G</au><au>Bouwer, Colin</au><au>Behnke, Kirsten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder</atitle><jtitle>International clinical psychopharmacology</jtitle><addtitle>Int Clin Psychopharmacol</addtitle><date>1997-10</date><risdate>1997</risdate><volume>12 Suppl 6</volume><spage>S27</spage><epage>S27</epage><pages>S27-S27</pages><issn>0268-1315</issn><eissn>1473-5857</eissn><abstract>Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compared with that of the selective serotonin reuptake inhibitor fluoxctine. The target dose of moclobemide was 450 mg/day in the dose range of 300–600 mg/day, while the target dose for fluoxetine was 20 nig/day in the dose range of 10–30 mg/day. There were two consecutive studies. The first was an 8-week short-term study of acute adverse events, tolerabilily and efficacy. The efficacy data showed no significant difference between moclobemide and fluoxetine. Evaluation of the tolerability in a long-term study of up to 1 year is still in progress. A review of the moclobemide safety database for panic disorder with 624 patients showed a marginal increase in events with moclobemide compared with placebo for insomnia (11.2%), dizziness (4.5%) and dry mouth (3.7%), with rates for headaches and nausea lower for moclobemide than placebo.These data suggest moclobemide is a well tolerated and effective treatment for panic disorder.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>9466172</pmid><doi>10.1097/00004850-199710006-00006</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-1315 |
| ispartof | International clinical psychopharmacology, 1997-10, Vol.12 Suppl 6, p.S27-S27 |
| issn | 0268-1315 1473-5857 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00004850_199710006_00006 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Anxiety - drug therapy Anxiety - psychology Benzamides - adverse effects Benzamides - therapeutic use Biological and medical sciences Blood Pressure - drug effects Female Fluoxetine - adverse effects Fluoxetine - therapeutic use Humans Male Medical sciences Moclobemide Monoamine Oxidase Inhibitors - adverse effects Monoamine Oxidase Inhibitors - therapeutic use Neuropharmacology Panic Disorder - drug therapy Panic Disorder - psychology Pharmacology. Drug treatments Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Serotonin Uptake Inhibitors - adverse effects Serotonin Uptake Inhibitors - therapeutic use Time Factors |
| title | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T16%3A26%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Moclobemide%20for%20anxiety%20disorders:%20a%20focus%20on%20moclobemide%20for%20panic%20disorder&rft.jtitle=International%20clinical%20psychopharmacology&rft.au=Tiller,%20John%20W.G&rft.date=1997-10&rft.volume=12%20Suppl%206&rft.spage=S27&rft.epage=S27&rft.pages=S27-S27&rft.issn=0268-1315&rft.eissn=1473-5857&rft_id=info:doi/10.1097/00004850-199710006-00006&rft_dat=%3Cpubmed_cross%3E9466172%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9466172&rfr_iscdi=true |